{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:32:56Z","timestamp":1785396776599,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Chemotherapy-induced febrile neutropenia (FN) is a life-threatening and chemotherapy dose-limiting adverse event. FN can be prevented with granulocyte-colony stimulating factors (G-CSFs). Guidelines recommend primary G-CSF use for patients receiving either high (&gt;\u200920%) FN risk (HR) chemotherapy, or intermediate (10\u201320%) FN risk (IR) chemotherapy if the overall risk with additional patient-related risk factors exceeds 20%. In this study, we applied an EHR text-mining tool for real-world G-CSF treatment evaluation in breast cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Breast cancer patients receiving IR or HR chemotherapy treatments between January 2015 and February 2021 at LUMC, the Netherlands, were included. We retrospectively collected data from EHR with a text-mining tool and assessed G-CSF use, risk factors, and the FN and neutropenia (grades 3\u20134) and incidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 190 female patients were included, who received 77 HR and 113 IR treatments. In 88.3% of the HR regimens, G-CSF was administered; 7.3% of these patients developed FN vs. 33.3% without G-CSF. Although most IR regimen patients had\u2009\u2265\u20092 risk factors, only 4% received G-CSF, of which none developed neutropenia. However, without G-CSF, 11.9% developed FN and 31.2% severe neutropenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our text-mining study shows high G-CSF use among HR regimen patients, and low use among IR regimen patients, although most had\u2009\u2265\u20092 risk factors. Therefore, current practice is not completely in accordance with the guidelines. This shows the need for increased awareness and clarity regarding risk factors. Also, text-mining can effectively be implemented for the evaluation of patient care.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00520-022-07343-5","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T06:04:44Z","timestamp":1661925884000},"page":"9181-9189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world evaluation of supportive care using an electronic health record text-mining tool: G-CSF use in breast cancer patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Sylvia A.","family":"van Laar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim B.","family":"Gombert-Handoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Wassenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Zwaveling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"issue":"5","key":"7343_CR1","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/ACM.0000000000003122","volume":"95","author":"E Teisberg","year":"2020","unstructured":"Teisberg E, Wallace S, O\u2019Hara S (2020) Defining and implementing value-based health care: a strategic framework. Acad Med 95(5):682\u2013685","journal-title":"Acad Med"},{"issue":"1","key":"7343_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-publhealth-032315-021353","volume":"37","author":"JA Casey","year":"2016","unstructured":"Casey JA, Schwartz BS, Stewart WF, Adler NE (2016) Using electronic health records for population health research: a review of methods and applications. Annu Rev Public Health 37(1):61\u201381","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"7343_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00392-016-1025-6","volume":"106","author":"MR Cowie","year":"2017","unstructured":"Cowie MR, Blomster JI, Curtis LH, Duclaux S, Ford I, Fritz F et al (2017) Electronic health records to facilitate clinical research. Clin Res Cardiol 106(1):1\u20139","journal-title":"Clin Res Cardiol"},{"issue":"21","key":"7343_CR4","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1158\/0008-5472.CAN-19-0579","volume":"79","author":"GK Savova","year":"2019","unstructured":"Savova GK, Danciu I, Alamudun F, Miller T, Lin C, Bitterman DS et al (2019) Use of natural language processing to extract clinical cancer phenotypes from electronic medical records. Cancer Res 79(21):5463\u20135470","journal-title":"Cancer Res"},{"issue":"1","key":"7343_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40264-018-0766-8","volume":"42","author":"F Liu","year":"2019","unstructured":"Liu F, Jagannatha A, Yu H (2019) Towards drug safety surveillance and pharmacovigilance: current progress in detecting medication and adverse drug events from electronic health records. Drug Saf 42(1):95\u201397","journal-title":"Drug Saf"},{"key":"7343_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fmed.2019.00066","volume":"6","author":"M Assale","year":"2019","unstructured":"Assale M, Dui LG, Cina A, Seveso A, Cabitza F (2019) The revival of the notes field: leveraging the unstructured content in electronic health records. Front Med (Lausanne) 6:66","journal-title":"Front Med (Lausanne)"},{"key":"7343_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijmedinf.2019.02.008","volume":"125","author":"C Dreisbach","year":"2019","unstructured":"Dreisbach C, Koleck TA, Bourne PE, Bakken S (2019) A systematic review of natural language processing and text mining of symptoms from electronic patient-authored text data. Int J Med Inform 125:37\u201346","journal-title":"Int J Med Inform"},{"issue":"1","key":"7343_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12911-017-0519-0","volume":"17","author":"T Delespierre","year":"2017","unstructured":"Delespierre T, Denormandie P, Bar-Hen A, Josseran L (2017) Empirical advances with text mining of electronic health records. BMC Med Inform Decis Mak 17(1):127","journal-title":"BMC Med Inform Decis Mak"},{"issue":"5","key":"7343_CR9","doi-asserted-by":"crossref","first-page":"e1266","DOI":"10.1002\/cnr2.1266","volume":"3","author":"SJ Zardawi","year":"2020","unstructured":"Zardawi SJ, Nordman I, Zdenkowski N (2020) A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens. Cancer Rep (Hoboken) 3(5):e1266","journal-title":"Cancer Rep (Hoboken)"},{"issue":"1","key":"7343_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Lago LD, Donnelly JP, Kearney N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"issue":"4","key":"7343_CR11","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00520-020-05715-3","volume":"29","author":"A Averin","year":"2021","unstructured":"Averin A, Silvia A, Lamerato L, Richert-Boe K, Kaur M, Sundaresan D et al (2021) Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Support Care Cancer 29(4):2179\u20132186","journal-title":"Support Care Cancer"},{"issue":"4","key":"7343_CR12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/ajco.13152","volume":"15","author":"M Lee","year":"2019","unstructured":"Lee M, Yee J, Kim JY, Kim JY, An SH, Lee KE et al (2019) Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim. Asia Pac J Clin Oncol 15(4):231\u2013237","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"7343_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190\u2013199","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"7343_CR14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00520-018-4473-x","volume":"27","author":"JP Salmon","year":"2019","unstructured":"Salmon JP, Smakal M, Karanikiotis C, Wojtukiewicz MZ, Omnes Y, DeCosta L et al (2019) Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin\u2019s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study. Support Care Cancer 27(4):1449\u20131457","journal-title":"Support Care Cancer"},{"issue":"4","key":"7343_CR15","first-page":"171","volume":"29","author":"J Krol","year":"2006","unstructured":"Krol J, Paepke S, Jacobs VR, Paepke D, Euler U, Kiechle M et al (2006) G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients. Onkologie 29(4):171\u2013178","journal-title":"Onkologie"},{"key":"7343_CR16","doi-asserted-by":"publisher","first-page":"103193","DOI":"10.1016\/j.critrevonc.2020.103193","volume":"157","author":"P Lapidari","year":"2021","unstructured":"Lapidari P, Vaz-Luis I, Di Meglio A (2021) Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: a systematic review. Crit Rev Oncol Hematol 157:103193","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"7343_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10549-016-3954-1","volume":"159","author":"T Younis","year":"2016","unstructured":"Younis T, Rayson D, Jovanovic S, Skedgel C (2016) Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review. Breast Cancer Res Treat 159(3):425\u2013432","journal-title":"Breast Cancer Res Treat"},{"issue":"34","key":"7343_CR18","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1200\/JCO.2012.48.3644","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM et al (2013) Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol 31(34):4283\u20134289","journal-title":"J Clin Oncol"},{"issue":"1","key":"7343_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","volume":"18","author":"PS Becker","year":"2020","unstructured":"Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R et al (2020) NCCN Guidelines insights hematopoietic growth factors version 1. J Natl Compr Canc Netw 18(1):12\u201322","journal-title":"J Natl Compr Canc Netw"},{"issue":"28","key":"7343_CR20","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"9","key":"7343_CR21","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00520-020-05295-2","volume":"28","author":"PL Gawade","year":"2020","unstructured":"Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA et al (2020) Patterns of granulocyte colony\u2013stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 28(9):4413\u20134424","journal-title":"Support Care Cancer"},{"issue":"1","key":"7343_CR22","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1038\/s41467-020-16138-3","volume":"11","author":"S de Groot","year":"2020","unstructured":"de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG et al (2020) Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun 11(1):3083","journal-title":"Nat Commun"},{"issue":"3","key":"7343_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/cpt.1966","volume":"108","author":"SA van Laar","year":"2020","unstructured":"van Laar SA, Gombert-Handoko KB, Guchelaar H-J, Zwaveling J (2020) An electronic health record text mining tool to collect real-world drug treatment outcomes: a validation study in patients with metastatic renal cell carcinoma. Clin Pharmacol Ther 108(3):644\u2013652","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"7343_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdn560","volume":"20","author":"P Jenkins","year":"2009","unstructured":"Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 20(1):34\u201340","journal-title":"Ann Oncol"},{"issue":"2","key":"7343_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00520-017-3863-9","volume":"26","author":"RK Goyal","year":"2018","unstructured":"Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA (2018) Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer 26(2):539\u2013548","journal-title":"Support Care Cancer"},{"issue":"7","key":"7343_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.annonc.2020.04.005","volume":"31","author":"M Clemons","year":"2020","unstructured":"Clemons M, Fergusson D, Simos D, Mates M, Robinson A, Califaretti N et al (2020) A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. Ann Oncol 31(7):951\u2013957","journal-title":"Ann Oncol"},{"issue":"12","key":"7343_CR27","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1007\/s00520-018-4280-4","volume":"26","author":"J Bacrie","year":"2018","unstructured":"Bacrie J, Laurans M, Iorio P, Fourme E, Volters AB, Bozec L et al (2018) Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution. Support Care Cancer 26(12):4097\u20134103","journal-title":"Support Care Cancer"},{"issue":"11","key":"7343_CR28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M et al (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16(11):1299\u20131309","journal-title":"Support Care Cancer"},{"issue":"1","key":"7343_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12885-018-4365-y","volume":"18","author":"S Liutkauskiene","year":"2018","unstructured":"Liutkauskiene S, Grizas S, Jureniene K, Suipyte J, Statnickaite A, Juozaityte E (2018) Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. BMC Cancer 18(1):453","journal-title":"BMC Cancer"},{"issue":"8","key":"7343_CR30","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/cam4.454","volume":"4","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Dale DC, Legg JC, Abella E, Morrow PK, Whittaker S et al (2015) Assessing patients\u2019 risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? Cancer Med 4(8):1153\u20131160","journal-title":"Cancer Med"},{"issue":"16","key":"7343_CR31","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038\u20133051","journal-title":"J Clin Oncol"},{"issue":"10","key":"7343_CR32","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/13696998.2017.1358173","volume":"20","author":"A McBride","year":"2017","unstructured":"McBride A, Campbell K, Bikkina M, MacDonald K, Abraham I, Balu S (2017) Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 20(10):1083\u20131093","journal-title":"J Med Econ"},{"issue":"8","key":"7343_CR33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/13696998.2020.1760284","volume":"23","author":"A McBride","year":"2020","unstructured":"McBride A, Wang W, Campbell K, Balu S, MacDonald K, Abraham I (2020) Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. J Med Econ 23(8):856\u2013863","journal-title":"J Med Econ"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07343-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07343-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07343-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T09:43:47Z","timestamp":1700991827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07343-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7343"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07343-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"assertion":[{"value":"29 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Medical Ethics Review Committee of the LUMC, Leiden, who waived the need for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}